Idiopathic Pulmonary Fibrosis Clinical Trial
Official title:
Impact of a Systematic Palliative Care on Quality of Life, in Advanced Idiopathic Pulmonary Fibrosis (IPF). A Randomized Multi-center Trial.
Idiopathic pulmonary fibrosis (IPF) is a rare and severe disease with a survival median
between 2 and 4 years which leads to a profound alteration of the quality of life.
In thoracic oncology, the systematic and early intervention of a palliative care team result
in an improvement of quality of life for patients.
In the princeps study published in 2010, the early intervention of a dedicated palliative
care team was compared to standard care in a randomized trial of 150 patients and shows a
significant improvement : (i) of quality of life (main objective), (ii) of depression scores
and even overall survival (11.6 months vs. 8.9 months, P = 0.02), (iii) a benefit in terms of
understanding the diagnosis and therapeutic goals (3), (iv) diminution of adapted
hospitalization in end of life (in emergency or not).
Considering some analogy points between IPF and advanced lung cancer (prognosis, respiratory
symptom, psychological burden), it seemed reasonable to assume that the joint systematic
intervention of chest physician and palliative care team may provide a significant benefit in
terms of quality of life for patients with severe IPF.
Idiopathic pulmonary fibrosis (IPF) is a rare and severe disease with a survival median
between 2 and 4 years which leads to a profound alteration of the quality of life. This
alteration results from different consequences of the IPF: progressive shortness of breath,
irritative cough refractory to treatments, exhaustion, limitation of activity, social
isolation, and psychic consequences such as fear, anxiety and depression.
The only current curative treatment of the disease is pulmonary transplantation, but it's
only feasible for a minority of patients. Anti-fibrotic drugs, such as pirfenidone and
nintedanib, are likely to slow the progression of IPF but have no impact on patients' quality
of life.
The symptomatic treatment aimed at relieving respiratory discomfort and the patient's quality
of life is therefore fundamental, and the IPF meets in many ways the challenges of lung
cancer.
In thoracic oncology, the systematic and early intervention of a palliative care team result
in an improvement of quality of life for patients.
In the princeps study published in 2010, the early intervention of a dedicated palliative
care team was compared to standard care in a randomized trial of 150 patients and shows a
significant improvement : (i) of quality of life (main objective), (ii) of depression scores
and even overall survival (11.6 months vs. 8.9 months, P = 0.02), (iii) a benefit in terms of
understanding the diagnosis and therapeutic goals (3), (iv) diminution of adapted
hospitalization in end of life (in emergency or not).
Considering some analogy points between IPF and advanced lung cancer (prognosis, respiratory
symptom, psychological burden), it seemed reasonable to assume that the joint systematic
intervention of chest physician and palliative care team may provide a significant benefit in
terms of quality of life for patients with severe IPF.
Objective:
To investigate the benefit on quality of life, evaluated after 6 months, of a systematic,
formalized and joint intervention of a palliative intervention staff and a chest physician
team compared to standard care for patients with severe IPF.
Secondary endpoints
1. To evaluate the benefit of the systematic, formalized and joint intervention of a
palliative care team and a chest physician team on:
- Mood and depression
- Understanding of diagnosis and therapeutic objectives, frequency of drafting of
advance directives regarding end-of-life
- Respiratory symptoms (cough and dyspnea)
- The course of care, the use of palliative care stays and the duration of hospital
stays (number and duration of hospitalizations).
- Overall survival and place of death.
2. Carry out a medico-economic study evaluating the incremental cost-utility and
cost-effectiveness ratio (overall survival criterion)
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05984992 -
The First-in-human Study of SRN-001 in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT04312594 -
Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
Recruiting |
NCT03865927 -
GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
Completed |
NCT03979430 -
Early Detection of Acute Exacerbation in Patients With Idiopathic Lung Fibrosis - a Pilot Study
|
N/A | |
Enrolling by invitation |
NCT04905693 -
Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
|
Phase 3 | |
Terminated |
NCT04419558 -
Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 3 | |
Completed |
NCT03725852 -
A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
Terminated |
NCT03573505 -
An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
Recruiting |
NCT04148157 -
Quality of Life in IPF - Patient and Physician Perceptions
|
||
Active, not recruiting |
NCT03222648 -
Structured Exercise Training Programme in Idiopathic Pulmonary Fibrosis
|
N/A | |
Completed |
NCT02257177 -
RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients
|
Phase 1/Phase 2 | |
Completed |
NCT02268981 -
Effects of an Oxymizer® During Daytime in Patients With Pulmonary Fibrosis (IPF)
|
N/A | |
Withdrawn |
NCT01524068 -
A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations
|
Phase 2 | |
Enrolling by invitation |
NCT01382368 -
Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients
|
Phase 4 | |
Completed |
NCT01110694 -
Prospective Observation of Fibrosis in the Lung Clinical Endpoints Study
|
||
Completed |
NCT01199887 -
Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis
|
Phase 1 | |
Active, not recruiting |
NCT02951416 -
Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank
|
||
Terminated |
NCT00981747 -
Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis
|
Phase 2/Phase 3 | |
Completed |
NCT00540475 -
Pennsylvania Idiopathic Pulmonary Fibrosis Research Registry
|
||
Completed |
NCT00532233 -
SD, IL-13 Production Rate in IPF
|
Phase 2 |